EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Synthetic RNA Therapeutics in Cancer

Youngjin Han, Seung-Hyun Shin, Chang Gyu Lim, Yong Ho Heo, In Young Choi, Ha Hyung Kim

The Journal of Pharmacology and Experimental Therapeutics · 2023-08 · 386 (2) · 212-223

DOI: 10.1124/jpet.123.001587 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2023-08. Verfasst von Youngjin Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hanmi Research Center, Hanmi Pharmaceutical Co. Ltd., Gyeonggi-do, Republic of Korea (Y.H., S.-H.S., C.G.L., Y.H.H., I.Y.C.); and Biotherapeutics and…. Hauptthemen laut MEDLINE: MicroRNAs, Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 132 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent advances in the RNA delivery system have facilitated the development of a separate field of RNA therapeutics, with modalities including mRNA, microRNA (miRNA), antisense oligonucleotide (ASO), small interfering RNA, and circular (circRNA) that have been incorporated into oncology research. The main advantages of the RNA-based modalities are high flexibility in designing RNA and rapid production for clinical screening. It is challenging to eliminate tumors by tackling a single target in cancer. In the era of precision medicine, RNA-based therapeutic approaches potentially constitute suitable platforms for targeting heterogeneous tumors that possess multiple sub-clonal cancer cell populations. In this review, we discussed how synthetic coding and non-coding RNAs, such as mRNA, miRNA, ASO, and circRNA, can be applied in the development of therapeutics. SIGNIFICANCE STATEMENT: With development of vaccines against coronavirus, RNA-based therapeutics have received attention. Here, the authors discuss different types of RNA-based therapeutics potentially effective against tumor that are highly heterogeneous giving rise to resistance and relapses to the conventional therapeutics. Moreover, this study summarized recent findings suggesting combination approaches of RNA therapeutics and cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsNeoplasmsHumansRNARNA, CircularRNA, Small InterferingOligonucleotides, AntisenseRNA, Messenger

Substanzen

RNARNA, CircularMicroRNAsRNA, Small InterferingOligonucleotides, AntisenseRNA, Messenger

Autor:innen und Institutionen

  • Hanmi Research Center, Hanmi Pharmaceutical Co. Ltd., Gyeonggi-do, Republic of Korea (Y.H., S.-H.S., C.G.L., Y.H.H., I.Y.C.); and Biotherapeutics and Glycomics Laboratory, College of Pharmacy (Y.H.H., H.H.K.) and Depart…

Zitieren

APA

Han, Y., Shin, S. H., Lim, C. G., Heo, Y. H., Choi, I. Y., & Kim, H. H. (2023). Synthetic RNA Therapeutics in Cancer. The Journal of Pharmacology and Experimental Therapeutics, 386(2), 212-223. https://doi.org/10.1124/jpet.123.001587

Vancouver

Han Y, Shin SH, Lim CG, Heo YH, Choi IY, Kim HH. Synthetic RNA Therapeutics in Cancer. The Journal of Pharmacology and Experimental Therapeutics. 2023;386(2):212-223. doi:10.1124/jpet.123.001587

BibTeX
@article{Han2023,
  author = {Han, Youngjin and Shin, Seung-Hyun and Lim, Chang Gyu and Heo, Yong Ho and Choi, In Young and Kim, Ha Hyung},
  title = {Synthetic RNA Therapeutics in Cancer},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2023},
  volume = {386},
  number = {2},
  pages = {212--223},
  doi = {10.1124/jpet.123.001587}
}
Kostenlos starten →